NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Ascendis Pharma A/S ASND
11 fiscal years on record · EUR · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
€720.1M
▲ 98.0% vs FY2024
EPS · FY25
€-3.76
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-31.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 720.1M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 32 cents on every revenue dollar this year.
Per share
EUR -3.76
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-18.9%
Net margin-31.7%
Return on assets-18.4%
Returned to shareholders
EUR 17.4M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksEUR 17.4M
Share of profit-7.6%
Consecutive raises—
EUR 17.4M in buybacks went back to shareholders in a year without profit.
Growth
+153.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+141.4%
+153.0%
+56.6%
Returned to shareholders
−45.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 1.3B
total assets, end of FY2025
Total assetsEUR 1.3B
CashEUR 616.0M
Gross debtEUR 720.3M
Net debtEUR 104.2M
Current ratio1.04×
History
11 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue €B
0.7
0.4
0.3
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income €B
−0.1
−0.3
−0.5
−0.6
−0.5
−0.3
−0.2
−0.2
−0.1
−0.1
−0.0
EBITDA €B
·
·
·
·
·
·
·
·
·
·
·
Income tax €B
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Net income €B
−0.2
−0.4
−0.5
−0.6
−0.4
−0.4
−0.2
−0.1
−0.1
−0.1
−0.0
EPS, diluted €
−3.76
−6.53
−8.55
−10.40
−7.00
·
·
·
−3.68
−2.58
−1.39
Dividend / sh €
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
35 of 35
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed